AI-Driven Vaccine Development Aims for Pre-Emptive Protection Against Future Viruses
Researchers are leveraging Artificial Intelligence (AI) to revolutionize vaccine development, moving towards a proactive approach to pandemic preparedness. Instead of developing vaccines after an outbreak, the goal is to create broadly protective vaccines in advance, evaluate them in early-stage clinical trials, and potentially stockpile them before the next spillover event. Professor Jonathan Heeney and his team at DIOSynVax are using AI to design synthetic antigens that can trigger broad immune responses against multiple viral variants, including those that don't yet exist. This AI-leveraged platform analyzes vast amounts of viral sequences to identify conserved patterns, allowing for the engineering of novel antigens that represent a wide spectrum of potential variants. This method has already led to advanced clinical programs, such as a pan-sarbecovirus vaccine and a broadly protective hemorrhagic fever vaccine, with promising results in preclinical and early human trials.